Treatment with NF-κB inhibitors (such as CAT-1041 and edasalonexent) ameliorated dystrophic pathology in mdx mice and GRMD dogs (101) and has shown promise in a phase 1 clinical trial in DMD patients (102). The gene discussed is NFKB1; the disease is Duchenne muscular dystrophy.